RedShift BioAnalytics

RedShift BioAnalytics

Private
Boxborough, MassachusettsHealthcare & Life Scienceshttps://www.redshiftbio.com/

Last Round

Series E

Oct 18, 2021

Total Funding Raised

$70.18M

Company Overview

RedShift BioAnalytics is a life sciences company that provides a platform for biomolecule analysis through its proprietary Microfluidic Modulation Spectroscopy (MMS) technology.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Drug Discovery, Clinical Trials, Sensors

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Non-AI

Keywords

Microfluidic Modulation SpectroscopyMMSprotein characterizationprotein analysisbiophysical characterizationprotein secondary structureanalytical instrumentationbiotech equipmentprotein stability analysisformulation developmentdrug development toolsquality controlbiosimilar analysismAb analysisAAV analysisCDMO toolsFTIR alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RedShift BioAnalytics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

RedShift BioAnalytics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series EOct 18, 2021
Series D ExtensionFeb 18, 2021
Series DJan 29, 2020
Series CMar 8, 2017
Series BApr 11, 2013
Series A
Jan 12, 2006

Key People

Founding team and executive leadership

Eugene Ma

Co-founder & CTO

Founding Team

Tom O'Lenic

Chief Executive Officer

Executive Team

Dennis Merrill

Chief Operating Officer

Executive Team

RedShift BioAnalytics Investors

Notable investors and investment history

InvestorRounds
Technology Venture PartnersSeries E, Series A, Series B, Series C, Series D Extension, Series D
Waters CorporationSeries D Extension, Series D, Series E, Series C
Illumina VenturesSeries E

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 2, 2025

    Monthly visitors increased 82% MoM, reaching 6.2K.

  • May 3, 2025

    Monthly visitors increased 48% MoM.

RedShift BioAnalytics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RedShift BioAnalytics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RedShift BioAnalytics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoxborough, Massachusetts
Employee Range25
Year Founded2005
Last FundingOct 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.